Blood Measurement of NET Transcripts (NETest) Predicts Well-Differentiated Gastroenteropancreatic NET Disease Status and Is Prognostic for Disease Progression Abstract #1569

Introduction: A key issue in GEP-NETs is early identification and prediction of disease progression. Clinical evaluation and imaging are limited due to the lack of sensitivity and disease indolence.
Aim(s): Assess the NETest as a predictive and prognostic marker of progression in a long-term follow-up study.
Materials and methods: GEP-NETs (n=34) followed for a median 4 yrs (2.2-5.4). WHO tumor grade/stage Grade I: n=15, Grade II: n=17; 31 (91%): stage IV. Baseline and longitudinal imaging and biomarkers were available and progression defined (RECIST 1.0). NETest: qPCR and multianalyte algorithmic analysis (disease activity scaled 0-100% with low <40% and high activity risk cutoffs >80%); CgA: RIA (normal <150µg/l); PFS: Kaplan-Meier analysis.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Keywords: PCR

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1190 Blood Gene Transcript Analysis Predicts 68Ga- SSA-PET/CT Imaging in Neuroendocrine Tumors and Defines Disease Status
Introduction: Limitations of biomarkers and imaging are a concern in the identification of NET status and therapy response.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
Authors: Bodei L, Kidd M, Modlin I, Drozdov I, ...
#957 Outcome Predictors of Gastrinomas: The Role of ENETS Staging, Grading and Interdisciplinary Treatment
Introduction: Gastrinomas are rare neuroendocrine neoplasias (NEN) presenting with Zollinger‐Ellison‐syndrome (ZES).
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: M.A. Stephan Felder
Authors: Felder S, Jann H, Tischer E, Pascher A, ...
#1151 Gastric Neuroendocrine Neoplasias-Outcome Predictors-ENETS Staging and Grading System and Treatment
Introduction: Detailed analysis to guide management decisions in gNEN is rare.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: M.A. Stephan Felder
Authors: Felder S, Jann H, Gerlach U, Pascher A, ...
#897 A Molecular Multi-Transcript Gene Blood Signature Significantly Outperforms Chromogranin A (CgA) in the Detection of Gut Neuroendocrine Tumors (NETs)
Introduction: A key issue in NET management is the need for a specific and sensitive biomarker to detect disease and assess treatment. CgA is widely utilized but has limitations.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Professor Irvin M Modlin
Authors: Modlin I M, Kidd M, Drozdov I, Alaimo D, ...
Keywords: biomarker, CgA, NET, PCR
#913 A PCR-Based Multigene Transcript Analysis Blood Test Outperforms Chromogranin A in the Detection of Gastrointestinal and Pancreatic Neuroendocrine Tumors and is Unaffected by PPI Use or Hypertension
Introduction: A critical requirement in the management of gut NETs is a blood biomarker test that is sensitive, specific and reproducible.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Professor Irvin M Modlin
Keywords: biomarker, CgA, NET, PCR
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.